|
1
|
Oberstein PE and Olive KP: Pancreatic
cancer: Why is it so hard to treat? Therap Adv Gastroenterol.
6:321–337. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 22:9694–9705.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Xu XH, Zeng XY, Wang LJ, Liu YN, Liu JM,
Qi JL, Yin P and Zhou MG: The disease burden of pancreatic cancer
in China in 1990 and 2017. Zhonghua Liu Xing Bing Xue Za Zhi.
40:1084–1088. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
5
|
GBD 2017 Pancreatic Cancer Collaborators.
The global, regional, and national burden of pancreatic cancer and
its attributable risk factors in 195 countries and territories,
1990-2017: A systematic analysis for the Global Burden of Disease
Study 2017. Lancet Gastroenterol Hepatol. 4:934–947.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Li Y, Vandenboom TG II, Wang Z, Kong D,
Ali S, Philip PA and Sarkar FH: MiR-146a suppresses invasion of
pancreatic cancer cells. Cancer Res. 70:1486–1495. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Brunner M, Wu Z, Krautz C, Pilarsky C,
Grützmann R and Weber GF: Current clinical strategies of pancreatic
cancer treatment and open molecular questions. Int J Mol Sci.
20(4543)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Duguang L, Jin H, Xiaowei Q, Peng X,
Xiaodong W, Zhennan L, Jianjun Q and Jie Y: The involvement of
lncRNAs in the development and progression of pancreatic cancer.
Cancer Biol Ther. 18:927–936. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
He Y, Hu H, Wang Y, Yuan H, Lu Z, Wu P,
Liu D, Tian L, Yin J, Jiang K and Miao Y: ALKBH5 inhibits
pancreatic cancer motility by decreasing long non-coding RNA
KCNK15-AS1 methylation. Cell Physiol Biochem. 48:838–846.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Deng SJ, Chen HY, Ye Z, Deng SC, Zhu S,
Zeng Z, He C, Liu ML, Huang K, Zhong JX, et al: Hypoxia-induced
LncRNA-BX111 promotes metastasis and progression of pancreatic
cancer through regulating ZEB1 transcription. Oncogene.
37:5811–5828. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lei Y, Wang YH, Wang XF and Bai J:
LINC00657 promotes the development of colon cancer by activating
PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 22:6315–6323.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sun Y, Wang J, Pan S, Yang T, Sun X, Wang
Y, Shi X, Zhao X, Guo J and Zhang X: LINC00657 played oncogenic
roles in esophageal squamous cell carcinoma by targeting miR-615-3p
and JunB. Biomed Pharmacother. 108:316–324. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bi S, Wang Y, Feng H and Li Q: Long
noncoding RNA LINC00657 enhances the malignancy of pancreatic
ductal adenocarcinoma by acting as a competing endogenous RNA on
microRNA-433 to increase PAK4 expression. Cell Cycle. 19:801–816.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang J, Wang B, Ren H and Chen W: MiR-9-5p
inhibits pancreatic cancer cell proliferation, invasion and
glutamine metabolism by targeting GOT1. Biochem Biophys Res Commun.
509:241–248. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tian S, Guo X, Yu C, Sun C and Jiang J:
MiR-138-5p suppresses autophagy in pancreatic cancer by targeting
SIRT1. Oncotarget. 8:11071–11082. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yao R, Xu L, Wei B, Qian Z, Wang J, Hui H
and Sun Y: MiR-142-5p regulates pancreatic cancer cell
proliferation and apoptosis by regulation of RAP1A. Pathol Res
Pract. 215(152416)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang F, Xue X, Wei J, An Y, Yao J, Cai H,
Wu J, Dai C, Qian Z, Xu Z and Miao Y: hsa-miR-520h downregulates
ABCG2 in pancreatic cancer cells to inhibit migration, invasion,
and side populations. Br J Cancer. 103:567–574. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gao H, Gong N, Ma Z, Miao X, Chen J, Cao Y
and Zhang G: LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth
and invasion through regulating the miR-204/HMGB1 axis. Int J Biol
Macromol. 116:545–551. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wei W, Liu Y, Lu Y, Yang B and Tang L:
LncRNA XIST promotes pancreatic cancer proliferation through
miR-133a/EGFR. J Cell Biochem. 118:3349–3358. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
van Roessel S, Kasumova GG, Verheij J,
Najarian RM, Maggino L, de Pastena M, Malleo G, Marchegiani G,
Salvia R, Ng SC, et al: International validation of the eighth
edition of the American joint committee on cancer (AJCC) TNM
staging system in patients with resected pancreatic cancer. JAMA
Surg. 153(e183617)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zeng Z, Gao ZL, Zhang ZP, Jiang HB, Yang
CQ, Yang J and Xia XB: Downregulation of CKS1B restrains the
proliferation, migration, invasion and angiogenesis of
retinoblastoma cells through the MEK/ERK signaling pathway. Int J
Mol Med. 44:103–114. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hwang JS, Jeong EJ, Choi J, Lee YJ, Jung
E, Kim SK, Min JK, Han TS and Kim JS: MicroRNA-1258 inhibits the
proliferation and migration of human colorectal cancer cells
through suppressing CKS1B expression. Genes (Basel).
10(912)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang J, Liu X, Yu G, Liu L, Wang J, Chen
X, Bian Y, Ji Y, Zhou X, Chen Y, et al: UBE2C is a potential
biomarker of intestinal-type gastric cancer with chromosomal
instability. Front Pharmacol. 9(847)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Goral V: Pancreatic cancer: Pathogenesis
and diagnosis. Asian Pac J Cancer Prev. 16(5619)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang W, Lou W, Ding B, Yang B, Lu H, Kong
Q and Fan W: A novel mRNA-miRNA-lncRNA competing endogenous RNA
triple sub-network associated with prognosis of pancreatic cancer.
Aging (Albany NY). 11:2610–2627. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang R, Niu Z, Pei H and Peng Z: Long
noncoding RNA LINC00657 induced by SP1 contributes to the non-small
cell lung cancer progression through targeting miR-26b-5p/COMMD8
axis. J Cell Physiol. 235:3340–3349. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shaker OG, Ali MA, Ahmed TI, Zaki OM, Ali
DY, Hassan EA, Hemeda NF and AbdelHafez MN: Association between
LINC00657 and miR-106a serum expression levels and susceptibility
to colorectal cancer, adenomatous polyposis, and ulcerative colitis
in Egyptian population. IUBMB Life. 71:1322–1335. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu H, Li J, Koirala P, Ding X, Chen B,
Wang Y, Wang Z, Wang C, Zhang X and Mo YY: Long non-coding RNAs as
prognostic markers in human breast cancer. Oncotarget.
7:20584–20596. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang XM, Wang J, Liu ZL, Liu H, Cheng YF
and Wang T: LINC00657/miR-26a-5p/CKS2 ceRNA network promotes the
growth of esophageal cancer cells via the MDM2/p53/Bcl2/Bax
pathway. Biosci Rep. 40(BSR20200525)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chu L, Yu L, Liu J, Song S, Yang H, Han F,
Liu F and Hu Y: Long intergenic non-coding LINC00657 regulates
tumorigenesis of glioblastoma by acting as a molecular sponge of
miR-190a-3p. Aging (Albany NY). 11:1456–1470. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu
Z and Li H: MiR-520g and miR-520h overcome bortezomib resistance in
multiple myeloma via suppressing APE1. Cell Cycle. 18:1660–1669.
2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Su JL, Chen PB, Chen YH, Chen SC, Chang
YW, Jan YH, Cheng X, Hsiao M and Hung MC: Downregulation of
microRNA miR-520h by E1A contributes to anticancer activity. Cancer
Res. 70:5096–5108. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhou T, Wu L, Ma N, Tang F, Zong Z and
Chen S: LncRNA PART1 regulates colorectal cancer via targeting
miR-150-5p/miR-520h/CTNNB1 and activating Wnt/β-catenin pathway.
Int J Biochem Cell Biol. 118(105637)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Stella F, Pedrazzini E, Baialardo E, Fantl
DB, Schutz N and Slavutsky I: Quantitative analysis of CKS1B mRNA
expression and copy number gain in patients with plasma cell
disorders. Blood Cells Mol Dis. 53:110–117. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Shrestha S, Yang CD, Hong HC, Chou CH, Tai
CS, Chiew MY, Chen WL, Weng SL, Chen CC, Chang YA, et al:
Integrated MicroRNA-mRNA analysis reveals miR-204 inhibits cell
proliferation in gastric cancer by targeting CKS1B, CXCL1 and
GPRC5A. Int J Mol Sci. 19(87)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Fujita Y, Yagishita S, Hagiwara K,
Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H,
Tamura T, et al: The clinical relevance of the
miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant
non-small-cell lung cancer. Mol Ther. 23:717–727. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hu M, Wang M, Lu H, Wang X, Fang X, Wang
J, Ma C, Chen X and Xia H: Loss of miR-1258 contributes to
carcinogenesis and progression of liver cancer through targeting
CDC28 protein kinase regulatory subunit 1B. Oncotarget.
7:43419–43431. 2016.PubMed/NCBI View Article : Google Scholar
|
